Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 0.67 |
| ▸ | CA1 | P00915 | 10/20 | 0.67 |
| ▸ | CA2 | P00918 | 10/20 | 0.67 |
| ▸ | CA9 | Q16790 | 10/20 | 0.67 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981652 | 0.99 | MEN1 (0.97) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL13204703 | 0.97 | MEN1 (0.95) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL13204667 | 0.90 | MEN1 (0.81) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2969028 | 0.89 | MEN1 (0.81) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2978970 | 0.89 | MEN1 (0.81) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2977101 | 0.89 | MEN1 (0.79) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2970463 | 0.87 | MEN1 (0.78) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2979747 | 0.87 | MEN1 (0.78) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2979379 | 0.87 | MEN1 (0.76) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL2985683 | 0.87 | MEN1 (0.76) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | claimed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | claimed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | claimed |
| WO-2024144816-A1 | TREATMENT OF IMMUNOLOGICALLY COLD SOLID TUMORS | CANTEX PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | claimed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | claimed |
| EP-3194572-B1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RES & DEV (IL) | 2023-10-25 | — | — | EP | claimed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-10-06 | — | — | US | claimed |
| US-20220307034-A1 | INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION | THE CLEVELAND CLINIC FOUNDATION | 2022-09-29 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | claimed |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | claimed |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-10-27 | — | — | US | claimed |
| WO-2010053573-A2 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | KAWAOKA YOSHIHIRO (US) | 2010-05-14 | — | — | WO | claimed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | claimed |
| WO-2026098574-A1 | DRUG FOR BRONCHOPULMONARY DYSPLASIA AND USE METHOD THEREFOR | 中国福利会国际和平妇幼保健院 | 2026-05-15 | — | — | WO | disclosed |
| EP-4735462-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735463-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570957-B2 | Isolated naive pluripotent stem cells and methods of generating same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-10 | — | — | US | disclosed |
| US-20260028583-A1 | ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-01-29 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12460207-B2 | Inhibiting APE2 expression in a subject treated with a drug agent that causes increased APE2 expression | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12427149-B2 | Methods and compositions for the prevention and treatment of hearing loss | Ting Theropeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12414981-B2 | JNK inhibitors for use in treating and preventing neurodegenerative disorders | NORTHWESTERN UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250270310-A1 | TREATMENT OF KIDNEY INJURY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-08-28 | — | — | US | disclosed |
| US-12390479-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | KNOW BIO, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250237642-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | UNIV EMORY (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4565577-A1 | INHIBITORS AND USES THEREFOR | Macquarie University (AU) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145945-A1 | CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION | ACCELLTA LTD. (IL) | 2025-05-08 | — | — | US | disclosed |
| CN-113677706-B | Treatment of liver toxicity | 新加坡保健服务私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250127786-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250099454-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| US-20250092126-A1 | TREATMENT AND PREVENTION OF ALCOHOLIC LIVER DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| US-12252709-B2 | Culture media for culturing pluripotent stem cells in suspension | ACCELLTA LTD. (IL) | 2025-03-18 | — | — | US | disclosed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | disclosed |
| US-12234284-B2 | Treatment of kidney injury | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-02-25 | — | — | US | disclosed |
| WO-2025028555-A1 | CASK DISORDER TREATING AGENT AND TREATMENT METHOD | 国立大学法人信州大学 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025000059-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025000061-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240408145-A1 | Gene Therapy | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-12-12 | — | — | US | disclosed |
| EP-3914698-B1 | CULTURE MEDIA FOR PLURIPOTENT STEM CELLS | YEDA RES & DEV (IL) | 2024-12-11 | — | — | EP | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4469049-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2024-12-04 | — | — | EP | disclosed |
| US-12157768-B2 | Anti-LILRB2 antibodies and methods of use thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | disclosed |
| CN-118767143-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118785907-A | Combination of 8-chloro-N- (4- (trifluoromethoxy) phenyl) quinolin-2-amine and its derivatives with a JAK inhibitor | ABIVAX公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240318144-A1 | MEDIA FOR CULTURING NAIVE HUMAN PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4419543-A1 | GENE THERAPY | Ospedale San Raffaele S.r.l. (IT) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-3221446-B1 | IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS | GENOME RES LTD (GB) | 2024-08-21 | — | — | EP | disclosed |
| CN-114981298-B | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240262857-A1 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | EMORY UNIVERSITY | 2024-08-08 | — | — | US | disclosed |
| US-20240261243-A1 | NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE | KNOW BIO, LLC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410832-A2 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | Biora Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-3554342-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | BIORA THERAPEUTICS INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024144816-A1 | TREATMENT OF IMMUNOLOGICALLY COLD SOLID TUMORS | CANTEX PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4376948-A1 | TREATMENT AND PREVENTION OF ALCOHOLIC LIVER DISEASE | Boehringer Ingelheim International GmbH (DE) | 2024-06-05 | — | — | EP | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240156913-A1 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2024-05-16 | — | — | US | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| US-20240139315-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| CN-110430801-B | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117769427-A | Modified nucleosides and nucleotide analogues as antiviral agents for coronaviruses and other viruses | 埃默里大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11920164-B2 | Media for culturing naive human pluripotent stem cells | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| US-11913018-B2 | In vitro production of expanded potential stem cells | GENOME RESEARCH LIMITED (GB) | 2024-02-27 | — | — | US | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-111655228-B | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024026540-A1 | INHIBITORS AND USES THEREFOR | MACQUARIE UNIVERSITY (AU) | 2024-02-08 | — | — | WO | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11883491-B2 | Compositions and methods for prevention and treatment of hearing loss | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3880673-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| US-20230399393-A1 | METHODS TO EXTEND HEALTH-SPAN AND TREAT AGE-RELATED DISEASES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-12-14 | — | — | US | disclosed |
| CN-117209447-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117143042-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11813270-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | KNOW BIO, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813311-B2 | Treatment and prevention of metabolic diseases | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2023-11-14 | — | — | US | disclosed |
| EP-3194572-B1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RES & DEV (IL) | 2023-10-25 | — | — | EP | disclosed |
| US-11787858-B2 | Anti-LILRB3 antibodies and methods of use thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| EP-4252629-A2 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Biora Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116829583-A | Methods for extending the health period and treating age-related disorders | 新加坡国立大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023172635-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | EMORY UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116726362-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4237448-A1 | METHODS TO EXTEND HEALTH-SPAN AND TREAT AGE-RELATED DISEASES | National University of Singapore (SG) | 2023-09-06 | — | — | EP | disclosed |
| CN-111094243-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4232146-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | Biora Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4208029-A1 | NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE | KNOW Bio, LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230212279-A1 | TREATMENT AND PREVENTION OF DISEASE CAUSED BY TYPE IV COLLAGEN DYSFUNCTION | SINGAPORE HEALTH SERVICES PTE, LTD. (SG) | 2023-07-06 | — | — | US | disclosed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| WO-2023066735-A1 | GENE THERAPY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-04-27 | — | — | WO | disclosed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023054395-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | 住友ファーマ株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054396-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | 住友化学株式会社 | 2023-04-06 | — | — | WO | disclosed |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2023006765-A1 | TREATMENT AND PREVENTION OF ALCOHOLIC LIVER DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| US-20220403017-A1 | TREATMENT OF KIDNEY INJURY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-12-22 | — | — | US | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| WO-2022251663-A2 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | EMORY UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4093205-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW Bio, LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220362335-A1 | JNK INHIBITORS FOR USE IN TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | NORTHWESTERN UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-10-27 | — | — | US | disclosed |
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | IFM MANAGEMENT, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4073102-A2 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217154-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220313696-A9 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220307034-A1 | INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION | THE CLEVELAND CLINIC FOUNDATION | 2022-09-29 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11433073-B2 | Compositions and methods for the prevention and treatment of hearing loss | TING THERAPEUTICS LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| CN-114981298-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20220265660-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022170396-A1 | AGENTS AND METHODS FOR THERAPY AND PROPHYLAXIS | ViraLok Therapeutics Pty Ltd (AU) | 2022-08-18 | — | — | WO | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-11377636-B2 | Endogenous retrovirus transcription as a marker for primate naive pluripotent stem cells | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-07-05 | — | — | US | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20220160736-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW BIO LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-11339216-B2 | Treatment of kidney injury | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-05-24 | — | — | US | disclosed |
| US-20220152063-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW BIO LLC (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220145264-A1 | CULTURE MEDIUM FOR MAMMALIAN EXPANDED POTENTIAL STEM CELLS, COMPOSITION, AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022090509-A1 | METHODS TO EXTEND HEALTH-SPAN AND TREAT AGE-RELATED DISEASES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-05-05 | — | — | WO | disclosed |
| US-11319368-B2 | Treatment of hepatotoxicity with IL-11 antibody | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2022-05-03 | — | — | US | disclosed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114364693-A | Treatment and prevention of metabolic disorders | 新加坡保健服务私人有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2022051606-A1 | NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE | KNOW BIO, LLC (US) | 2022-03-10 | — | — | WO | disclosed |
| EP-3962936-A1 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Singapore Health Services Pte. Ltd. (SG) | 2022-03-09 | — | — | EP | disclosed |
| US-20220056128-A1 | ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-24 | — | — | US | disclosed |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3947642-A1 | CULTURE MEDIUM FOR MAMMALIAN EXPANDED POTENTIAL STEM CELLS, COMPOSITION, AND METHODS THEREOF | The University of Hong Kong (CN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113966393-A | Culture medium, composition and method for expanding latent energy stem cells of mammals | 香港大学 | 2022-01-21 | — | — | CN | disclosed |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-07-20 | — | — | US | disclosed |
| US-11052090-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11045474-B2 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections | EMORY UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112804994-A | Method for treating myeloproliferative tumors | 卡托斯医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3801476-A2 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3750544-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF VIRAL INFECTION | Emory University (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200352948-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2020-11-12 | — | — | US | disclosed |
| US-10821111-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200316073-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111655228-A | Compositions and methods for preventing and treating hearing loss | J·左 | 2020-09-11 | — | — | CN | disclosed |
| US-10765679-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200206229-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2020-07-02 | — | — | US | disclosed |
| EP-2785184-B1 | COMPOSITIONS COMPRISING JAK INHIBITORS AND HAART DRUGS FOR USE IN THE PREVENTION OR TREATMENT OF HIV | UNIV EMORY (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200093923-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVEN (US) | 2020-03-26 | — | — | US | disclosed |
| EP-3618807-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | Zuo, Jian (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20190134039-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-05-09 | — | — | US | disclosed |
| WO-2018204226-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-11-08 | — | — | WO | disclosed |
| US-10022378-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022378-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170312283-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2017-11-02 | — | — | US | disclosed |
| US-20170312283-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2017-11-02 | — | — | US | disclosed |
| US-20170191038-A1 | TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE | HONG GUAN LTD (CN) | 2017-07-06 | — | — | US | disclosed |
| US-9662332-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9662332-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | disclosed |
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | disclosed |
| WO-2017007712-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | EMORY UNIVERSITY (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | disclosed |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | disclosed |
| US-9222118-B2 | Screen for inhibitors of filovirus and uses therefor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9222118-B2 | Screen for inhibitors of filovirus and uses therefor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9089574-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9089574-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013082476-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| WO-2010053573-A2 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | KAWAOKA YOSHIHIRO (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053573-A2 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | KAWAOKA YOSHIHIRO (US) | 2010-05-14 | — | — | WO | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| EP-1463735-B1 | IMIDAZO¬2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS INC (CA) | 2009-08-12 | — | — | EP | disclosed |
| EP-1463735-B1 | IMIDAZO¬2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS INC (CA) | 2009-08-12 | — | — | EP | disclosed |
| US-20090179638-A1 | ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090179638-A1 | ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| EP-2012782-A1 | USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | Aegera Therapeutics Inc. (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| WO-2007118318-A1 | USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| WO-2007087716-A1 | ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS | AEGERA THERAPEUTICS INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885CA12 2839/4885 |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | MEN1 3603/4885KMT2A 1555/4885CA12 3066/4885 |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | MEN1 1150/4885KMT2A 723/4885CA12 4748/4885 |
| US-20260028583-A1 | ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAME | PRKD3, GSK3B, GSK3A | MEN1 3714/4885KMT2A 955/4885CA12 4532/4885 |
| US-10821111-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | MEN1 4875/4885KMT2A 253/4885CA12 4773/4885 |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | MEN1 4875/4885KMT2A 253/4885CA12 4773/4885 |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | MEN1 1260/4885KMT2A 4184/4885CA12 488/4885 |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, JAK1, PDPK1 | MEN1 1475/4885KMT2A 445/4885CA12 4734/4885 |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | MEN1 3932/4885KMT2A 4575/4885CA12 188/4885 |
| US-12390479-B2 | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | NOS1, NOS2, NOS3 | MEN1 3202/4885KMT2A 3019/4885CA12 4564/4885 |
| US-12570957-B2 | Isolated naive pluripotent stem cells and methods of generating same | GSK3B, EZH2, GSK3A | MEN1 3667/4885KMT2A 313/4885CA12 4433/4885 |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2749/4885KMT2A 3879/4885CA12 4598/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885CA12 2839/4885 |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885CA12 2839/4885 |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | MEN1 3389/4885KMT2A 2979/4885CA12 4706/4885 |
| US-20200352948-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | MEN1 4793/4885KMT2A 130/4885CA12 4832/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3277/4885KMT2A 4465/4885CA12 2844/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | MEN1 903/4885KMT2A 3139/4885CA12 275/4885 |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | MEN1 4796/4885KMT2A 168/4885CA12 4674/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | MEN1 1475/4885KMT2A 445/4885CA12 4734/4885 |
| US-20200206229-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | MEN1 4875/4885KMT2A 253/4885CA12 4773/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | MEN1 4796/4885KMT2A 168/4885CA12 4674/4885 |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3294/4885KMT2A 4417/4885CA12 3146/4885 |
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | NLRP3, NLRP1, TNF | MEN1 4298/4885KMT2A 4750/4885CA12 3752/4885 |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3988/4885KMT2A 2903/4885CA12 2416/4885 |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA12 3878/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MEN1 1822/4885KMT2A 1324/4885CA12 4586/4885 |
| US-20220160736-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | MEN1 3202/4885KMT2A 3019/4885CA12 4564/4885 |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | PMP22, SMN1; SMN2, BDNF | MEN1 3442/4885KMT2A 3774/4885CA12 3873/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3418/4885KMT2A 4433/4885CA12 2983/4885 |
| US-20220152063-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | MEN1 3202/4885KMT2A 3019/4885CA12 4564/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MEN1 3988/4885KMT2A 2903/4885CA12 2416/4885 |
| US-20190134039-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | MEN1 4875/4885KMT2A 253/4885CA12 4773/4885 |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA12 3878/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 2868/4885KMT2A 2653/4885CA12 1332/4885 |
| US-20240408145-A1 | Gene Therapy | MCL1, DNASE1L3, CDKN1A | MEN1 3359/4885KMT2A 764/4885CA12 4688/4885 |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | MEN1 1932/4885KMT2A 2906/4885CA12 1344/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | MEN1 3046/4885KMT2A 300/4885CA12 4746/4885 |
| US-20240261243-A1 | NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE | NOS2, NOS1, NOS3 | MEN1 1564/4885KMT2A 4126/4885CA12 3092/4885 |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2619/4885KMT2A 3882/4885CA12 4645/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885CA12 2839/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885CA12 2839/4885 |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | SI, VIP, MLN | MEN1 2076/4885KMT2A 4477/4885CA12 2674/4885 |
| US-10022378-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | MEN1 4875/4885KMT2A 253/4885CA12 4773/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | MEN1 2273/4885KMT2A 2785/4885CA12 1470/4885 |
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2749/4885KMT2A 3879/4885CA12 4598/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | MEN1 3159/4885KMT2A 2061/4885CA12 4128/4885 |
| US-20250099454-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | JAK2, JAK1, JAK3 | MEN1 1600/4885KMT2A 99/4885CA12 3782/4885 |
| US-20200316073-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | MEN1 3046/4885KMT2A 300/4885CA12 4746/4885 |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | MEN1 3046/4885KMT2A 300/4885CA12 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.